News

According to new research, pregnancy does not increase the risk of recurrence for women who have had early breast cancer.

For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.

Patients with lung cancer who received low-dose CT scans had a 15% to 20% lower risk of death from their disease versus those who had standard chest X-rays, which has led to screening guidelines.

Barriers to clinical trials can more acutely affect patients in minority and other groups -- such as the elderly.

Maintenance rucaparib may improves progression-free survival in patients with ovarian cancer.

Clinicals can use mutiple-gene panels to identify mutations to test for breast cancer and ovarian cancer risk.

The Visible Ink program at Memorial Sloan Kettering Cancer Center helps patients and survivors express their stories and feelings through writing.

Inaccurate ideas of palliative care can negative effect the outcomes for patients with lung cancer.

The occurence of hand-foot skin response could signal regorafenib activity in hepatocellular cancer.

For patients with high-risk melanoma, the best option is effective adjuvant therapy which necessitates clincal trials.

The risk of developing certain types of cancer can be increased by exposure to work-related stress.

The FDA accepted supplemental biologics license application (sBLA) for the use of denosumab (Xgeva) for the prevention of skeletal-related events (SREs) in patients with multiple myeloma.

The indication for the DigniCap Cooling System has been expanded by the FDA to include alopecia reduction across all solid tumors.

The US Preventive Services Task Force (USPSTF) does not agree with the need for yearly full-body skin exams, which many healthcare providers support.

Anne Llewellyn had been a nurse in the Emergency Department and Respiratory Intensive Care for almost 40 years when she was diagnosed with a central nervous system brain tumor.

The FDA has approved ClearLLab multicolor reagents for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms.

A trial testing the combination of ublituximab, ibrutinib, and umbralisib showed that the combination was well tolerated and had activity across patients with high-risk B-cell malignancies.

The abilities of the caregiver of a patient with glioblastoma multiforme may affect that patient's survival.

Jennifer Ligibel, MD, discusses Breast Cancer Weight Loss Study and how a weight loss intervention may help patients with breast cancer.

Researchers found that the rate of suicide in patients with lung cancer is much higher than those with other types of cancer.

There are specific challenges when treating AYA patients with Hodgkin lymphoma.

Among long-term CRC survivors, regular use of aspirin is associated with overall survival and use of NSAIDs was significantly associated with improved survival only in individuals with KRAS wild-type tumors.

The Biden Cancer Initiative has named Kim Thiboldeaux, the CEO of Cancer Support Community, to its Board of Directors.

A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.

The FDA has approved the dabrafenib/trametinib combination for patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC)

As the Senate revealed their healthcare reconciliation bill, healthcare advocacy and profession organizations weighed in.

The FDA has approved subcutaneous rituxumab (Rituxan Hycela) for the treatment of adults with previously untreated

The use of standard criteria for palliative care consultations in patients with advanced cancer is associated with an improvement in the quality of oncology care, as well as a reduction in downstream healthcare utilization.

The Insitute for Clinical Immuno-Oncology (ICLIO) are supporting multidisciplinary cancer teams to better deliver new and emerging cancer therapies.